.2
FibroBiologics Announces Closing of $3 Million Public Offering
HOUSTON, TX, April 2, 2026 -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,272,728 shares of common stock (the “Warrants”), at a combined public offering price of $1.32 per share (or per common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants have an exercise price of $1.32 per share and are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the “Stockholder Approval”) and will expire on the five-year anniversary of the date of Stockholder Approval.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering were approximately $3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Warrants, if fully exercised on a cash basis, will be approximately $3 million. No assurance can be given that any of the Warrants will be exercised. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
The securities described above were being offered pursuant to a registration statement on Form S-1 (File No. 333-294713), which was declared effective by the Securities and Exchange Commission (the "SEC") on March 31, 2026. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. Electronic copies of the final prospectus may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About FibroBiologics, Inc.
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.